Pharmacogenomics

Pushing the envelope on personalized medicine

Recognizing the powerful role genes can play in diagnosing illness and guiding treatment, the Division of Laboratory Genetics and Genomics at Mayo Clinic spearheaded a testing expansion, implementing and upgrading more than 60 advanced sequencing and biochemical assays in 2023 and planning for even more this year.

By Robin Huiras-Carlson • February 21, 2024
Ann Moyer, M.D., Ph.D., Makes a Case for Pharmacogenomics

Pharmacogenomic testing is still limited, despite ample research, the existence of guidelines, and the emerging evidence it can help patients. Ann Moyer, M.D., Ph.D., Co-Director of the Personalized Genomics Laboratory at Mayo Clinic in Rochester, Minnesota, makes a case for pharmacogenomics.

By Kelley Luedke • July 2, 2018
NUDT15: An Additional Gene Important in Prediction of Thiopurine-Related Toxicity [Test in Focus]

Ann Moyer, M.D., Ph.D., discusses an additional gene, NUDT15, which is important in the prediction of thiopurine-related toxicity This gene has been added to our TPMT genotyping assay available through Mayo Medical Laboratories.

By Mayo Clinic Laboratories • October 25, 2017
TPMT Testing in Treatment of Inflammatory Bowel Disease [Test in Focus]

Detection of individuals with low thiopurine methyltransferase (TPMT) activity who are at risk for excessive myelosuppression or severe hematopoietic toxicity when taking thiopurine drugs.

By Mayo Clinic Laboratories • March 29, 2017